|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0007634,
umls-concept:C0008633,
umls-concept:C0017262,
umls-concept:C0017337,
umls-concept:C0020792,
umls-concept:C0086418,
umls-concept:C0185117,
umls-concept:C0205314,
umls-concept:C0205360,
umls-concept:C0332307,
umls-concept:C0336791,
umls-concept:C0678226,
umls-concept:C0679622,
umls-concept:C1158478,
umls-concept:C1705422,
umls-concept:C1999216,
umls-concept:C2252854,
umls-concept:C2911684
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2001-10-11
|
|
pubmed:abstractText |
Inhibitors of human 5alpha-reductase type II are promising drug candidates for the treatment of benign prostatic hyperplasia which is associated with high prostatic DHT levels. In this study we describe the evaluation of potential inhibitors in a new cell assay. First a plasmid (pRcCMV-5alphaII) for the expression of human 5alpha-reductase type II was constructed by the use of the vector pRcCMV and transfected into the African green monkey fibroblast-like cell line COS1. By selection with G418 sulfate, ten COS1 single cell clones were obtained of which three stably exhibited high 5alpha-reductase activity. One single cell clone (COS1-5alphaIIST) was selected for further investigations. By Southern blot analysis, fluorescence in situ hybridization (FISH) and comparative PCR experiments it turned out that the expression plasmid pRcCMV-5alphaII has been integrated into the chromosome, resulting in a long-term stable expression of the foreign 5alpha-reductase gene. The newly established cell line was used for testing novel compounds on their inhibitory effect on human 5alpha-reductase type II. Using this whole cell assay, inhibitors with IC(50) values in the nanomolar range could be identified.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0960-0760
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
78
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
275-84
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:11595508-Androstenedione,
pubmed-meshheading:11595508-Animals,
pubmed-meshheading:11595508-Base Sequence,
pubmed-meshheading:11595508-COS Cells,
pubmed-meshheading:11595508-Cholestenone 5 alpha-Reductase,
pubmed-meshheading:11595508-Chromosome Mapping,
pubmed-meshheading:11595508-DNA Primers,
pubmed-meshheading:11595508-Dihydrotestosterone,
pubmed-meshheading:11595508-Drug Evaluation, Preclinical,
pubmed-meshheading:11595508-Enzyme Inhibitors,
pubmed-meshheading:11595508-Gene Expression,
pubmed-meshheading:11595508-Humans,
pubmed-meshheading:11595508-Isoenzymes,
pubmed-meshheading:11595508-Male,
pubmed-meshheading:11595508-Oxidoreductases,
pubmed-meshheading:11595508-Plasmids,
pubmed-meshheading:11595508-Prostatic Hyperplasia,
pubmed-meshheading:11595508-Recombinant Proteins,
pubmed-meshheading:11595508-Transfection
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
Stable expression of human 5alpha-reductase type II in COS1 cells due to chromosomal gene integration: a novel tool for inhibitor identification.
|
|
pubmed:affiliation |
FR 8.5 Pharmaceutical and Medicinal Chemistry, University of the Saarland, P.O. Box 151150, D-66041, Saarbrücken, Germany.
|
|
pubmed:publicationType |
Journal Article
|
